Cardiometabolic Effects of Dual GLP-1 and Glucagon Receptor Agonists: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Authors' conclusion
Dual GLP-1R/GCGR agonists consistently improved cardiometabolic risk factors across randomized clinical trials and may provide metabolic benefits beyond selective GLP-1R agonists.
Study context
- Population
- Adults with cardiometabolic disease in RCTs of dual GLP-1R/GCGR agonists with treatment duration ≥12 weeks; 47.3% male
- Participants
- 6,611 adults16 trials
- Comparison
- Dual GLP-1R/GCGR agonists vs placebo
- Outcome
- Placebo-corrected change in body weight
- Follow-up
- Baseline to end of treatment
Methodological detailsrandom-effects, prespecified subgroup analyses
- Random-effects
- Prespecified subgroup analyses
Pooled result
As reported in the abstract
Change in body weight vs placebo
Each group vs placeboChange in body weight, % (95% CI)
Dual GLP-1R/GCGR agonists
−7.44(−9.44 to −5.43)
Each group vs placeboChange in body weight, kg (95% CI)
Dual GLP-1R/GCGR agonists
−7.27(−9.28 to −5.27)
Further pooled results
| Outcome | Reduction in triglycerides (mmol/L) (95% CI) | |
|---|---|---|
| Triglyceridesvs selective GLP-1R agonists | −0.28 (−0.50 to −0.06) | |
| −0.6−0.4−0.200.2Difference, mmol/L (linear scale) |
Cardiometabolic risk factors
- Weight loss was accompanied by improvements across all cardiometabolic risk factors
Original publication
Cardiometabolic Effects of Dual GLP-1 and Glucagon Receptor Agonists: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care. Published 21 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →